CSIMarket Company Name, Ticker, Suppliers, else..
 
Cognition Therapeutics inc   (NASDAQ: CGTX)
 
Price: $1.0500 $0.04 3.960%
Day's High: $1.0700000524520874 Week Perf: -0.94 %
Day's Low: $ 1.01 30 Day Perf: 6.49 %
Volume (M): 376,937 52 Wk High: $ 2.67
Volume (M$): $ 0 52 Wk Avg: $1.31
Open: $1.01 52 Wk Low: $0.55



 Market Capitalization (Millions $) 95
 Shares Outstanding (Millions) 91
 Employees 14
 Revenues (TTM) (Millions $) -
 Net Income (TTM) (Millions $) -12
 Cash Flow (TTM) (Millions $) 20
 Capital Exp. (TTM) (Millions $) 0

Business Description


Cognition Therapeutics Inc. is a biotechnology company focused on developing therapies for neurodegenerative disorders, particularly Alzheimer's disease. The company aims to target the underlying mechanisms of cognitive decline and develop small molecule drugs that can restore cognitive function and slow disease progression. Cognition Therapeutics' innovative approach involves disrupting the interaction between a protein called Sigma-2 receptor and amyloid beta, a protein associated with Alzheimer's disease. By inhibiting this interaction, the company hopes to prevent the toxic effects of amyloid beta and potentially improve memory and cognition in affected individuals.


   Company Address: 2500 Westchester Ave. Purchase 10577 NY
   Company Phone Number: 481-2210   Stock Exchange / Ticker: NASDAQ CGTX


   

Stock Performances by Major Competitors

5 Days Decrease / Increase
     
AVXL   -10.8%    
LONA   -1.79%    
• View Complete Report
   



Clinical Study

Advances in Alzheimer’s Disease Treatment Cognition Therapeutics Completes Phase 2 Study Enrollment for Zervimesine...

Published Thu, Nov 13 2025 12:46 PM UTC

Alzheimer s disease (AD) stands as one of the most pressing public health challenges of our era, with trajectories marked by increasing prevalence rates among aging populations. In response to this crisis, Cognition Therapeutics, Inc. has made significant strides in developing novel therapeutic agents targeting the underlying pathophysiology of AD. This article examines the...
Clinical Study

Advancing Insights Zervimesine (CT1812) as a Potential Game-Changer in Early Alzheimers and Retinal Health

Published Wed, Sep 3 2025 11:45 AM UTC

Cognition Therapeutics, Inc. is making notable strides in the field of neurodegenerative disorders with its lead investigational product, zervimesine (CT1812). As a clinical-stage company focused on drugs for conditions like Alzheimer’s disease and age-related macular degeneration, Cognition s recent developments signal promising pathways for intervention in multiple debil...
Clinical Study

Cognition Therapeutics Financial Landscape Navigating Challenges Amid Institutional Investment

Published Thu, Aug 28 2025 10:45 AM UTC

Cognition Therapeutics Inc., a biotechnology company specializing in therapies for neurodegenerative diseases, has recently announced a significant registered direct offering of common stock valued at $30 million. This move indicates confidence from investors but simultaneously sheds light on the entity s financial performance amidst a challenging competitive landscape. Fin...
Clinical Study

Cognition Therapeutics Presented Data at Association for Research in Vision and Ophthalmology Showing Impact on Retin...

Published Fri, May 9 2025 7:53 PM UTC

Targeting Dry AMD: Cognition Therapeutics Unveils Promising Preclinical Data on Zervimesine for Retinal Cell HealthIn a significant advancement in the ongoing battle against neurodegenerative disorders, Cognition Therapeutics, Inc. (NASDAQ: CGTX), a pioneering clinical-stage biopharmaceutical company, has recently shared groundbreaking preclinical data at the esteemed Assoc...
Shares

Cognition Therapeutics Secures Extension from Nasdaq as Share Price Struggles Continue,

Published Wed, Mar 12 2025 8:05 PM UTC

Cognition Therapeutics Granted Extension for Compliance with Nasdaq Listing Requirements Amid Struggles in Share PricePURCHASE, N.Y. March 12, 2025 Cognition Therapeutics, Inc. (Nasdaq: CGTX), a clinical-stage biotech company focused on innovative treatments for neurodegenerative disorders, received a crucial extension from the Nasdaq Stock Market. This decision, communica...



Fundamental Analysis

Valuation Current
Price to Earnings PE Ratio (TTM) -
Price to Earnings PE Ratio (Expected) -
Price to Sales (TTM) -
Price to Sales (Expected) -
Price to Book 2.88
PEG (TTM) -

Financial Strength Current
Quick Ratio 6.24
Working Capital Ratio 7.03
Leverage Ratio (MRQ) 0.18
Total Debt to Equity -
Interest Coverage (TTM) -
Debt Coverage (TTM) -

Per Share Current
Earnings (TTM) -0.2 $
Revenues (TTM) -
Cash Flow (TTM) 0.22 $
Cash 0.38 $
Book Value 0.36 $
Dividend (TTM) 0 $

Efficiency Current
Revenue per Employee (TTM) -
Net Income per Employee (TTM) -871,786
Receivable Turnover Ratio (TTM) -
Inventory Turnover Ratio (TTM) -
Asset Turnover Ratio (TTM) -

Profitability Ratios Current
Gross Margin (MRQ) -
Operating Margin (MRQ) -
Net Margin (MRQ) -
Net Cash Flow Margin (MRQ) -
Effective Tax Rate (TTM) -

Management Effectiveness Current
Return On Assets (TTM) -
Return On Investment (TTM) -
Return On Equity (TTM) -
Dividend Yield -
Pay out Ratio (TTM) -






Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.